Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

10.03 +0.45 (+4.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,170,139
Open 9.630
Bid (Size) 10.00 (20)
Ask (Size) 10.03 (49)
Prev. Close 9.580
Today's Range 9.500 - 10.12
52wk Range 2.870 - 10.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 Analysts Have This to Say About Roivant Sciences
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
 
Via Benzinga

Performance

YTD
+40.28%
+40.28%
1 Month
+8.67%
+8.67%
3 Month
+31.11%
+31.11%
6 Month
+43.39%
+43.39%
1 Year
+150.12%
+150.12%

More News

Read More
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Why Shares of Roivant Sciences Jumped This Week
Via The Motley Fool
Analyst Expectations for Roivant Sciences's Future
Via Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
Via Benzinga
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
Via Benzinga
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Via The Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
Via The Motley Fool
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
Via Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
Via The Motley Fool
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Via Investor's Business Daily
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
From Lokavant
Via Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
From Lokavant
Via Business Wire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
Via InvestorPlace
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
From Covant Therapeutics
Via GlobeNewswire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Shares of Roivant Sciences Were Down Tuesday
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.